The ORAL Trials: Advancing Clinical Research for RA
Researchers are currently conducting clinical studies, called the ORAL trials, for patients with active rheumatoid arthritis (RA) at more than 350 locations across 35 countries worldwide. The ORAL trials are part of a large Phase 3 clinical trial program designed to test the effectiveness and safety of the investigational drug tasocitinib (CP-690,550), which is an oral pill for patients with RA.
The ORAL trials are made up of two different clinical trials. Should you decide to enroll, your study doctor will tell you which of the two trials is best for you, according to your treatment history.
If you are eligible, you will receive study-related medical care, including visits with a rheumatologist, at no cost.
Your study doctor will provide more detail about the study for which you are eligible.
Frequently asked questions about the ORAL trials
Learn more about clinical trials
For more information about the ORAL trials from ClinicalTrials.gov:
